Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EVX-02B

Other · developed by Evaxion Biotech

Phase 1/2 Most advanced trial (none active)
EVAX Developer
1 Registered trials

What is EVX-02B?

EVX-02B is an investigational agent administered intramuscularly.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
B
Drug type
Other
Therapy area
Oncology
Developer
Evaxion Biotech A/S (EVAX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04455503 Phase 1/2 Melanoma Stage IV Terminated EVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Melanoma Stage IIIMelanoma Stage IV

More from Evaxion Biotech

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EVAX page.

Follow EVAX, the company behind EVX-02B

See EVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EVAX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.